What to expect from Gilead's Q4 earnings?
Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q4 earnings results on Thursday, February 2nd, after market close.
The consensus EPS Estimate is $1.51 (-19.3% Y/Y) and the consensus Revenue Estimate is $6.63B (-8.4% Y/Y).
Over the last 2 years, GILD has beaten EPS estimates 88% of the time and has beaten revenue estimates 88% of the time.

Over the last 3 months, EPS estimates have seen 7 upward revisions and 8 downward. Revenue estimates have seen 11 upward revisions and 2 downward.

The company boosted its full-year 2022 outlook. Non-GAAP earnings per share is now projected at between $6.95 and $7.15 ($7.11 consensus), while total product sales are expected between $25.9B and $26.2B, compared to $24.5B and $25B before.
The US Supreme Court this month again declined to rehear Bristol-Myers Squibb's (BMY) case that seeks to reinstate a $1.2B patent settlement against Gilead Sciences.
The company also ended a partnership with Matinas Biopharma (MTNB) that aimed to develop an oral version of the COVID-19 therapy remdesivir.
Gilead instead has decided to work on its own oral nucleoside prodrug of remdesivir.
Last quarter, Gilead was hit in the quarter by a major decline in its COVID-19 treatment, Veklury (remdesivir). Sales plummeted 52% to $925M.
(GILD) is up 21% in the last one year.
The stock has a Seeking Alpha's Quant system rating and SA Authors rating of hold, while Wall Street average rates it at buy.
Recent earnings Analysis from our contributors:Gilead Sciences: What To Do Ahead Of Q4 2022 Financial Report